Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
Hana JelinkovaCenter of Molecular Biology and Genetics Department of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.
Stepan HrabovskyDepartment of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.
Martina OrsulovaDepartment of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.
Zuzana VrzalovaCenter of Molecular Biology and Genetics Department of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.
Veronika NavrkalovaCenter of Molecular Biology and Genetics Department of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.ORCID https://orcid.org/0000-0003-3020-1578
Eva BrhelovaCenter of Molecular Biology and Genetics Department of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.
Lenka BryjovaCenter of Molecular Biology and Genetics Department of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.ORCID https://orcid.org/0000-0002-8108-9750
Alena BulikovaDepartment of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.
Eva OndrouskovaCenter of Molecular Biology and Genetics Department of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.ORCID https://orcid.org/0000-0003-0830-0692
Marketa SejnohovaCenter of Molecular Biology and Genetics Department of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.
Frantisek FolberDepartment of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.
Petra SedováDepartment of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.
Jiri MayerDepartment of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.
Sarka PospisilovaCenter of Molecular Biology and Genetics Department of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.
Marie JarosovaCenter of Molecular Biology and Genetics Department of Internal Medicine, Hematology and Oncology University Hospital and Faculty of Medicine Brno Czechia.ORCID https://orcid.org/0000-0002-2194-3433
University Hospital Brno · CZCentral European Institute of Technology · CZ
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Near-haploid acute lymphoblastic leukemia is rare subgroup of the disease, which is very important due to very poor prognosis and resistance to treatment including novel monoclonal antibodies and CAR-T therapy.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Very rare near-haploid acute lymphoblastic leukemia resistant to immunotherapy and CAR-T therapy in 19-year-old male patient. · full record | OpenQuestion